Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Theratech and Proctor and Gamble partner in $35 million hormone replacement therapy deal:

This article was originally published in Clinica

Executive Summary

Procter & Gamble and Theratech are to develop a combined transdermal testosterone and estradiol/testosterone hormone replacement therapy patch for women. P&G will fund the project and provide milestone payments up to $35 million to Theratech. P&G will retain marketing rights except in Asia, although certain Asian countries may be included in the deal. The testosterone patch is in Phase II trials.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts